In April 2020, we began joint development of a lidocaine patch, which was being developed by MEDRx Co., Ltd. as a treatment for neuropathic pain after shingles (post-herpetic neuralgia).
This product is a new lidocaine patch that draws on MEDRx’s proprietary ILTS® (Ionic Liquid Transdermal System) technology using ionic liquids. It is being developed targeting the market for the lidocaine patch Lidoderm®.
Although DWTI’s chief focus is on the field of ophthalmology, we have decided to partake in this joint development with the aim of expanding our pipeline and fortifying a stable, medium- to long-term earnings base. We will continue to promote collaboration with other companies through such efforts.
|Clinical indication||Neuropathic pain|
|Development process||Filed NDA application (U.S.)|
|Collaborative development company||MEDRx Co., Ltd.|
- 2020.08Filed NDA application (U.S.)
- 2020.04Conducted collaborative development agreement with MEDRx.